Market Overview

Expectations For Regeneron No Longer Realistic; Analyst Downgrades

Share:
Expectations For Regeneron No Longer Realistic; Analyst Downgrades

Analysts at Baird Equity Research turned bearish on Regeneron Pharmaceuticals Inc (NASDAQ: REGN) as investor expectation for a recently launched drug may be too high. The firm's Brian Skorney downgrades Regeneron's stock rating from Neutral to Underperform with an unchanged $408 price target.

Regeneron and Sanofi SA (ADR) (NYSE: SNY) announced in DUPIXENT (dupilumab), the first and only biologic medicine approved for the treatment of adults with moderate-to-severe atopic dermatitis. The therapy began selling within a week and on Monday Sanofi provided an update to the therapy's performance in conjunction with its second quarter results.

Sales of Dupixent totaled $30 million in the second quarter, which is "nothing to scoff at," Skorney said in his downgrade note. However, investor expectations for a strong performance has "stretched the valuation beyond what is reasonable" based on the initial launch metrics (see Skorney's track record here).

In fact, investor expectation shifted from "high" in late April/May to "extraordinary" today, the analyst added. Meanwhile, buy-side analysts may have also gotten ahead of themselves in predicting Dupixent to outperform Novartis' blockbuster therapy, Cosentyx.

"We believe shares reflect a greater degree of optimism than is warranted," Skorney emphasized. "We continue to believe Dupixent will be a big drug, as reflected by our reiterated target price of $408."

Related Links:

Regeneron's Dupixent Passes The FDA Muster; Baird Sees Strong Lauch

Is It Time To Step To The Sidelines On Regeneron?

Latest Ratings for REGN

DateFirmActionFromTo
Aug 2020BenchmarkDowngradesBuyHold
Aug 2020Credit SuisseMaintainsOutperform
Aug 2020BMO CapitalMaintainsMarket Perform

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

 

Related Articles (REGN)

View Comments and Join the Discussion!

Posted-In: atopic dermatitisAnalyst Color Biotech Short Ideas Downgrades Analyst Ratings Trading Ideas General Best of Benzinga

Latest Ratings

StockFirmActionPT
MURBC CapitalMaintains57.0
MUDeutsche BankMaintains51.0
MUUBSMaintains61.0
MUMizuhoMaintains56.0
BHPCredit SuisseUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com